TY - JOUR
T1 - HIV multidrug class resistance prediction with a time sliding anchor approach
AU - The EuResist Network Study Group
AU - Arslan, Nurhan
AU - Eggeling, Ralf
AU - Reuter, Bernhard
AU - Van Leathem, Kristel
AU - Pingarilho, Marta
AU - Gomes, Perpetua
AU - Sonnerborg, Anders
AU - Kaiser, Rolf
AU - Zazzi, Maurizio
AU - Pfeifer, Nico
N1 - © The Author(s) 2025. Published by Oxford University Press.
PY - 2025
Y1 - 2025
N2 - Motivation: The emergence of multidrug class resistance (MDR) in Human Immunodeficiency Virus (HIV) is a rare but significant challenge in antiretroviral therapy (ART). MDR, which may arise from prolonged drug exposure, treatment failures, or transmission of resistant strains, accelerates disease progression and poses particular challenges in resource-limited settings with restricted access to resistance testing and advanced therapies. Early prediction of future MDR development is important to inform therapeutic decisions and mitigate its occurrence. Results: In this study, we employ various machine learning classifiers to predict future resistance to all four major antiretroviral drug classes using features extracted from clinical HIV sequence data. We systematically explore several variations of the problem that differ in the pre-existing resistance level and the temporal gap between sample collection and observed MDR occurrence. Our models show the ability to predict multidrug class resistance even in the most challenging variations, albeit at a reduced accuracy. Feature importance analysis reveals that our models primarily utilize known drug resistance mutations for easier classification tasks, but rely on new mutations for the difficult task of distinguishing four class drug resistance from three class drug resistance. Availability and implementation: All analysis was performed using the Euresist Integrated DataBase (EIDB). Researchers wishing to reproduce, validate or extend these findings can request access to the latest EIDB release via the Euresist Network.
AB - Motivation: The emergence of multidrug class resistance (MDR) in Human Immunodeficiency Virus (HIV) is a rare but significant challenge in antiretroviral therapy (ART). MDR, which may arise from prolonged drug exposure, treatment failures, or transmission of resistant strains, accelerates disease progression and poses particular challenges in resource-limited settings with restricted access to resistance testing and advanced therapies. Early prediction of future MDR development is important to inform therapeutic decisions and mitigate its occurrence. Results: In this study, we employ various machine learning classifiers to predict future resistance to all four major antiretroviral drug classes using features extracted from clinical HIV sequence data. We systematically explore several variations of the problem that differ in the pre-existing resistance level and the temporal gap between sample collection and observed MDR occurrence. Our models show the ability to predict multidrug class resistance even in the most challenging variations, albeit at a reduced accuracy. Feature importance analysis reveals that our models primarily utilize known drug resistance mutations for easier classification tasks, but rely on new mutations for the difficult task of distinguishing four class drug resistance from three class drug resistance. Availability and implementation: All analysis was performed using the Euresist Integrated DataBase (EIDB). Researchers wishing to reproduce, validate or extend these findings can request access to the latest EIDB release via the Euresist Network.
UR - http://www.scopus.com/inward/record.url?scp=105006513945&partnerID=8YFLogxK
U2 - 10.1093/bioadv/vbaf099
DO - 10.1093/bioadv/vbaf099
M3 - Article
C2 - 40421422
AN - SCOPUS:105006513945
SN - 2635-0041
VL - 5
JO - Bioinformatics Advances
JF - Bioinformatics Advances
IS - 1
M1 - vbaf099
ER -